期刊文献+

三维适形放疗联合TP方案化疗治疗食管癌术后纵隔淋巴结转移的临床观察 被引量:9

Clinical Observation of Three Dimensional Conformal Radiation Therapy Combined with TP Regimen Chemotherapy for Mediastinal Lymph Node Metastasis After Operation of Esophagus Cancer
下载PDF
导出
摘要 目的观察三维适形放疗(3DCRT)联合TP方案化疗治疗食管癌术后纵隔淋巴结转移的疗效。方法 84例食管癌术后纵隔淋巴结转移患者随机分为两组,单纯3DCRT组(A组)和3DCRT联合TP方案化疗组(B组),每组42例。A组患者仅接受3DCRT,B组患者接受3DCRT和TP方案化疗。分别评价两组的疗效和毒副反应。结果 A、B组1、2、3年生存率分别为28.6%、19.0%、7.1%和50.0%、26.2%、9.5%;两组有效率分别为76.2%、92.8%(P<0.05)。B组毒副反应较A组重,但经对症处理后均可缓解。结论 3DCRT联合TP方案化疗治疗食管癌术后纵隔淋巴结转移患者可提高其生存率和有效率。 Objective To observe the curative effect of three dimensional conformal radiation therapy(3DCRT) plus TP regimen chemotherapy in the treatment of mediastinal lymph node metastasis after operation of esophagus cancer.Methods Eighty four cases with mediastinal lymph node metastasis after operation of esophagus cancer were divided randomly into two groups:42 cases were treated with 3DCRT(named A group) ;another 42 cases with 3DCRT combined with TP regimen chemotherapy(named B group).The curative effect and toxicities of the two groups were evaluated respectively.Results The 1-,2-,3-year survival rates of A group and B group were 28.6%,19.0%,7.1% and 50.0%,26.2%,9.5% respectively.The overall response rates of A group and B group were 76.2% and 92.8%(P 0.05).The toxicities of B group which could be tolerated were higher than those of A group.Conclusion 3DCRT combined with TP regimen chemotherapy can improve the survival rate and overall response rate of patients with mediastinal lymph node metastasis after operation of esophagus cancer.
出处 《肿瘤基础与临床》 2010年第4期320-322,共3页 journal of basic and clinical oncology
关键词 食管癌 纵隔淋巴结转移 三维适形放疗 化疗 esophagus cancer mediastinal lymph node metastasis three dimensional conformal radiation therapy chemotherapy
  • 相关文献

参考文献5

二级参考文献37

  • 1Choy H, Devore RE , Hande KR. A phase Ⅱ study of paclitaxel,carboplatin and concurrent hyperfranction radiotherapy for locally advanced inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys,2000,47: 931-937.
  • 2Ratanatharthorn V , Lorvidhaya V , Maoleekoonpairioj S. Phase Ⅱ trial of paclitaxel , carboplatin and concurrent radiotherapy for locally advanced no-small cell lung cancer. Lung Cancer , 2001,31: 257-265 .
  • 3Lau D, Leigh B, Gandara D, et al. Twice-weekly paclitaxel and concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage Ⅲ non-small cell lung cancer: a California cancer consortiun phase Ⅱ trail. J Clin Oncol ,2001,19:442-447.
  • 4Langer CJ, Movsas B, Hudes R, et al. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung carcinoma: report of Fox chase cancer center study 94-001. Semin Oncol, 1997,24(4 Suppl 12) :89-95 .
  • 5Socinski MA,Rosenman JG, Schell MJ,et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage Ⅲ A/B non-small cell lung carcinoma: a modified phase Ⅰ/Ⅱ trail. Cancer ,2001,92:1213-1223.
  • 6Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with untreatable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Cancer , 1987,59: 1874-1881.
  • 7Chang A, Kim K, Glick J, et al. Phase Ⅱ study of taxol, merbarone and piroxantrone in stage Ⅳ non-small cell lung cancer: the East Cooperative Oncology Group results. J Natl Cancer Inst, 1993,85: 388-394.
  • 8Murchy WK, Fossella FV, Winn R J, et al. Phase Ⅱ study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst, 1993,85: 384-388.
  • 9Zanelli GD,Quaia M,Robieux I,et al. Paclitaxel as a radiosensitiser :a proposed schedule of administration based on in vitro data and pharmacokinetic calculations. Eur J Cancer , 1997,33:486-492.
  • 10Milas L, Hunter NR, Mason KA. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res, 1995,55: 3564-3568.

共引文献240

同被引文献56

引证文献9

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部